SG11201507288UA - Compositions and methods for treating non-alcoholic steatohepatitis - Google Patents
Compositions and methods for treating non-alcoholic steatohepatitisInfo
- Publication number
- SG11201507288UA SG11201507288UA SG11201507288UA SG11201507288UA SG11201507288UA SG 11201507288U A SG11201507288U A SG 11201507288UA SG 11201507288U A SG11201507288U A SG 11201507288UA SG 11201507288U A SG11201507288U A SG 11201507288UA SG 11201507288U A SG11201507288U A SG 11201507288UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- alcoholic steatohepatitis
- treating non
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791533P | 2013-03-15 | 2013-03-15 | |
| US201361793309P | 2013-03-15 | 2013-03-15 | |
| US201361817796P | 2013-04-30 | 2013-04-30 | |
| PCT/JP2014/058145 WO2014142364A2 (en) | 2013-03-15 | 2014-03-14 | Compositions and methods for treating non-alcoholic steatohepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507288UA true SG11201507288UA (en) | 2015-10-29 |
Family
ID=51538254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507288UA SG11201507288UA (en) | 2013-03-15 | 2014-03-14 | Compositions and methods for treating non-alcoholic steatohepatitis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9889108B2 (en) |
| EP (1) | EP2968245B1 (en) |
| JP (1) | JP6442412B2 (en) |
| KR (1) | KR20150127599A (en) |
| CN (1) | CN105592846A (en) |
| AU (1) | AU2014230444B2 (en) |
| CA (1) | CA2904129A1 (en) |
| PH (1) | PH12015502136A1 (en) |
| SG (1) | SG11201507288UA (en) |
| WO (1) | WO2014142364A2 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3797591A1 (en) | 2009-04-29 | 2021-03-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
| BRPI1014405A2 (en) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | pharmaceutical compositions comprising epa and a cardiovascular agent and methods of their use |
| KR20120016677A (en) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (en) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for reducing high sensitivity levels (hs-CRP) in a subject |
| HUE053111T2 (en) | 2012-06-29 | 2021-06-28 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester |
| WO2014057522A1 (en) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| EP2968245B1 (en) | 2013-03-15 | 2021-05-05 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| CN106714840A (en) * | 2014-09-25 | 2017-05-24 | 阿斯利康(瑞典)有限公司 | Combination of an omega-3 fatty acid and an sglt-2 inhibitor for treating diseases of the liver |
| JP6514720B2 (en) | 2015-01-21 | 2019-05-15 | 持田製薬株式会社 | Self-emulsifying composition of ω3 fatty acid |
| PE20180690A1 (en) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | OBETICOLIC ACID COMPOSITIONS AND METHODS OF USE |
| WO2016181221A1 (en) | 2015-05-13 | 2016-11-17 | Dignity Sciences Limited | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same |
| FR3036943A1 (en) * | 2015-06-02 | 2016-12-09 | Echosens | NON-INVASIVE HEPATIC LESION DETECTION DEVICE |
| US20160374975A1 (en) | 2015-06-26 | 2016-12-29 | Pronova Biopharma Norge As | Composition for treatment of nafld |
| TW201733582A (en) | 2016-03-28 | 2017-10-01 | 大日本住友製藥股份有限公司 | Pharmaceutical combination comprising FXR agonist and ARB |
| CN107630084A (en) * | 2016-07-18 | 2018-01-26 | 昆山德诺瑞尔生物科技有限公司 | The polygenic combination detection kit of nonalcoholic fatty liver disease |
| CN108265034A (en) * | 2016-12-30 | 2018-07-10 | 苏州和锐生物科技有限公司 | Hybridoma cell strain and its anti-CK18-M30 monoclonal antibodies of generation and application |
| MX2019009337A (en) * | 2017-02-07 | 2019-09-19 | Fresenius Kabi Deutschland Gmbh | Long-term efficacy of liver disease treatment with epa and dha. |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| CN109212044B (en) * | 2017-06-30 | 2021-11-26 | 南京济群医药科技股份有限公司 | Detection method of obeticholic acid related substances |
| US20210121493A1 (en) * | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| IL275002B2 (en) * | 2017-12-06 | 2024-04-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| PT4056176T (en) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
| CN110025591A (en) * | 2019-04-29 | 2019-07-19 | 郑州泰丰制药有限公司 | A kind of Austria's shellfish cholic acid self-emulsifiable preparation and its soft capsule |
| WO2021237143A1 (en) * | 2020-05-22 | 2021-11-25 | Durect Corporation | Treatment of non-alcoholic steatohepatitis (nash) |
| US11285108B1 (en) * | 2021-03-09 | 2022-03-29 | Naturalis S.A. | Phytosterols for the prevention or treatment of non-alcoholic steatohepatitis |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| WO2022246243A1 (en) * | 2021-05-21 | 2022-11-24 | HepQuant, LLC | Methods of defining functional change and slowing progression in chronic liver disease |
| CN114494114A (en) * | 2021-12-20 | 2022-05-13 | 上海品览数据科技有限公司 | Hidden column in structure professional wall column construction drawing based on deep learning and attribute identification method thereof |
| WO2024118705A1 (en) * | 2022-11-29 | 2024-06-06 | Neuro-Innovators, Llc | Neurorestoration compound implementing multiple neuroplasticity inducing mechanisms of action |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| NO154918C (en) | 1977-08-27 | 1987-01-14 | Bayer Ag | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE. |
| DE2951135A1 (en) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE |
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| JPS6051189A (en) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | Thiazolidine derivative and its preparation |
| US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| WO1985005029A1 (en) | 1984-05-09 | 1985-11-21 | Medaphore Inc. | Oral insulin and a method of making the same |
| US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| DE3543999A1 (en) | 1985-12-13 | 1987-06-19 | Bayer Ag | HIGH PURITY ACARBOSE |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| WO1989001773A1 (en) | 1987-08-27 | 1989-03-09 | Biotechnology Research Partners, Ltd. | Synovial phospholipases |
| US5019508A (en) | 1987-08-27 | 1991-05-28 | Biotechnology Research Partners, Ltd. | Synovial phospholipases |
| US5642868A (en) | 1990-05-02 | 1997-07-01 | The United States Of America As Represented By The Secretary Of The Navy | Ceramic material |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes |
| US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| DE19534996A1 (en) | 1995-09-21 | 1997-03-27 | Bosch Gmbh Robert | Process for misfire detection by evaluating speed fluctuations |
| AU4050797A (en) | 1996-08-02 | 1998-02-25 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| US6423754B1 (en) | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
| AU9291198A (en) | 1997-09-30 | 1999-04-23 | Beki Ab | Apoptosis-related compounds and their use |
| HUP0101792A3 (en) | 1998-05-12 | 2003-01-28 | Wyeth Corp | Benzothiophenes, benzofurans, and indoles, their use for producing medicaments and this medicaments useful in the treatment of insulin resistance and hyperglycemia |
| JP2002514638A (en) | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | 11-aryl-benzo [B] naphtho [2,3-D] furans and 11-aryl-benzo [B] naphtho [2,3-D] thiophenes useful for the treatment of insulin resistance and hyperglycemia |
| JP2002514635A (en) | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | Biphenyloxo-acetic acid useful for treating insulin resistance and hyperglycemia |
| WO1999058522A1 (en) | 1998-05-12 | 1999-11-18 | American Home Products Corporation | Naphtho[2,3-b]heteroar-4-yl derivatives |
| WO2002026707A1 (en) | 2000-09-26 | 2002-04-04 | Biovitrum Ab | Novel compounds |
| AU2001292480A1 (en) | 2000-09-26 | 2002-04-08 | Biovitrum Ab | Novel pyridazine compounds for the treatment of diabetes |
| JP2002114768A (en) | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2-(2,5-dihalogen-3,4-dihyroxyphenyl)azole and medicinal composition containing the same |
| US20040191926A1 (en) | 2001-09-26 | 2004-09-30 | Zhong-Yin Zhang | Ptp1b inhibitors and ligands |
| EP1446110A2 (en) | 2001-10-16 | 2004-08-18 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
| US7022730B2 (en) | 2001-10-19 | 2006-04-04 | Transtech Pharma, Inc. | Bis-heteroaryl alkanes as therapeutic agents |
| US6642381B2 (en) | 2001-12-27 | 2003-11-04 | Hoffman-La Roche Inc. | Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors |
| ES2226549B1 (en) | 2002-12-18 | 2006-07-16 | One Way Liver Genomics, S.L. | METHOD FOR THE DIAGNOSIS OF NON-ALCOHOLIC ESTEATOHEPATITIS (NASH) THROUGH THE USE OF MOLECULAR MARKERS. |
| US20070105954A1 (en) | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| JP2007315752A (en) | 2004-08-16 | 2007-12-06 | Ajinomoto Co Inc | Judging method of hepatic fibrillation stage |
| EP1782807B1 (en) | 2004-08-18 | 2017-08-09 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
| WO2007016390A1 (en) | 2005-07-28 | 2007-02-08 | Children's Medical Center Corporation | Matrix metalloproteinase inhibitors for treating fatty liver disease |
| JP2007236253A (en) | 2006-03-07 | 2007-09-20 | Toray Ind Inc | Method for detecting disease or disease marker |
| US20070218579A1 (en) | 2006-03-17 | 2007-09-20 | Sharp Laboratories Of America, Inc. | Wide output swing CMOS imager |
| PL2189155T3 (en) | 2006-04-12 | 2016-07-29 | Unilever Nv | Oral composition with an antiageing effect on the skin |
| WO2007136674A1 (en) | 2006-05-19 | 2007-11-29 | The Cleveland Clinic Foundation | Detection and monitoring of liver damage |
| EP2777701A1 (en) | 2006-05-31 | 2014-09-17 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid |
| EP2105447A4 (en) | 2006-12-20 | 2010-05-05 | Shino Test Corp | Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1 |
| WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| WO2008156662A1 (en) | 2007-06-14 | 2008-12-24 | George Mason Intellectual Properties, Inc. | Methods of diagnosing non-alcoholic steatohepatitis (nash) |
| JPWO2009028457A1 (en) * | 2007-08-29 | 2010-12-02 | 国立大学法人信州大学 | Non-alcoholic steatohepatitis drug |
| JP2009120607A (en) | 2007-10-25 | 2009-06-04 | Kanazawa Univ | New prophylaxis or therapeutic agent for hepatic disease, and insulin resistance ameliorating agent |
| GB0807605D0 (en) | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| US20110082119A1 (en) | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| US20110092592A1 (en) * | 2008-06-13 | 2011-04-21 | Takashi Yano | Diagnosis and treatment of hepatic disorder |
| JPWO2009154230A1 (en) | 2008-06-17 | 2011-12-01 | 持田製薬株式会社 | Non-alcoholic steatohepatitis prevention / improvement / treatment drug |
| KR20110039249A (en) * | 2008-07-07 | 2011-04-15 | 모치다 세이야쿠 가부시키가이샤 | Ameliorating or therapeutic agent for dyslipidemia |
| JP2011006380A (en) | 2009-05-22 | 2011-01-13 | Mochida Pharmaceut Co Ltd | EMULSIFIED COMPOSITION OF ω3 FATTY ACID |
| CA2762939C (en) * | 2009-05-22 | 2017-07-18 | Mochida Phamaceutical Co., Ltd. | Self-emulsifying composition of .omega.3 fatty acid |
| US9060981B2 (en) | 2009-10-16 | 2015-06-23 | Mochida Pharmaceutical Co., Ltd. | Marker associated with non-alcoholic steatohepatitis |
| JP2013537186A (en) | 2010-09-08 | 2013-09-30 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | Composition comprising fatty acid oil mixture, free fatty acid and statin |
| JP5820256B2 (en) | 2011-02-10 | 2015-11-24 | 株式会社ファンケル | Self-emulsifying formulation |
| US20120264824A1 (en) * | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| CA2865030C (en) | 2012-02-29 | 2021-04-27 | B. Braun Melsungen Ag | Hormone containing emulsion |
| WO2014057522A1 (en) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| EP2719382A1 (en) | 2012-10-12 | 2014-04-16 | Mochida Pharmaceutical Co., Ltd. | Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| EP2968245B1 (en) | 2013-03-15 | 2021-05-05 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2015053379A1 (en) | 2013-10-07 | 2015-04-16 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
-
2014
- 2014-03-14 EP EP14764694.7A patent/EP2968245B1/en active Active
- 2014-03-14 KR KR1020157023331A patent/KR20150127599A/en active IP Right Grant
- 2014-03-14 AU AU2014230444A patent/AU2014230444B2/en not_active Ceased
- 2014-03-14 JP JP2015545545A patent/JP6442412B2/en active Active
- 2014-03-14 SG SG11201507288UA patent/SG11201507288UA/en unknown
- 2014-03-14 WO PCT/JP2014/058145 patent/WO2014142364A2/en active Application Filing
- 2014-03-14 CN CN201480014985.1A patent/CN105592846A/en active Pending
- 2014-03-14 US US14/775,452 patent/US9889108B2/en active Active
- 2014-03-14 CA CA2904129A patent/CA2904129A1/en not_active Abandoned
-
2015
- 2015-09-15 PH PH12015502136A patent/PH12015502136A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6442412B2 (en) | 2018-12-19 |
| US20160030378A1 (en) | 2016-02-04 |
| CA2904129A1 (en) | 2014-09-18 |
| EP2968245A4 (en) | 2016-10-05 |
| EP2968245B1 (en) | 2021-05-05 |
| EP2968245A2 (en) | 2016-01-20 |
| AU2014230444B2 (en) | 2018-05-17 |
| WO2014142364A2 (en) | 2014-09-18 |
| JP2016510720A (en) | 2016-04-11 |
| PH12015502136A1 (en) | 2016-01-25 |
| KR20150127599A (en) | 2015-11-17 |
| US9889108B2 (en) | 2018-02-13 |
| CN105592846A (en) | 2016-05-18 |
| AU2014230444A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201507288UA (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| EP3054940A4 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| IL281058A (en) | Compositions and methods for treating anemia | |
| IL245281A0 (en) | Methods and compositions for treating cancer | |
| HK1214521A1 (en) | Compositions and methods for treating proteinopathies | |
| SG10201707319UA (en) | Compositions and methods for treating mpsi | |
| ZA201505390B (en) | Compositions and methods for treating pests | |
| HK1217650A1 (en) | Compositions and methods for treating severe pain | |
| HK1225647A1 (en) | Compositions and methods for treating cancers | |
| HK1219884A1 (en) | Methods and compositions for treating leukemia | |
| EP3065550A4 (en) | Methods and compositions for treating sepsis | |
| ZA201503474B (en) | Compositions and methods for treating bacterial infections | |
| SG11201510300RA (en) | Compositions and methods for treating skin | |
| HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
| IL243022B (en) | Compositions and methods for post-harvest treatment | |
| HK1222323A1 (en) | Compositions and methods for treating conditions that affect epidermis | |
| EP2971044A4 (en) | Compositions and methods for treating cancer | |
| GB201302472D0 (en) | Compositions and methods for treating biofilms | |
| GB201302474D0 (en) | Compositions and methods for treating biofilms | |
| GB201302475D0 (en) | Compositions and methods for treating biofilms |